Document is current
Any future updates will be listed below
-
Authors
Schleimer, Lauren E.
Rousian, Merve
Alessandris, Remo
Kalvin, Hannah L.
Poletto, Edoardo
Jolissaint, Joshua S.
van Verschuer, Victorien
Balachandran, Vinod P.
Drebin, Jeffrey
D’Angelica, Michael I.
de Jonge, Jeroen
Kingham, T. Peter
Polak, Wojciech
Porte, Robert J.
Soares, Kevin C.
Wei, Alice C.
Gonen, Mithat
Jarnagin, William R.
Groot Koerkamp, Bas
- License Information
-
More Information
Article History
First Online: 28 April 2026
Disclosure
: V. P. Balachandran reports research funding from Genentech/Roche and is an inventor on patent applications related to antigen cross-reactivity and neoantigen quality modelling. J Jolissaint reports travel support from Boston Scientific and Intuitive J. Drebin reports employment and leadership at American Regent (spouse) and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. A.C. Wei reports consulting roles at HistoSonic and institutional research funding from Ipsen. M. Gonen reports funding for travel, accommodations, and expenses from Genentech. B. Groot Koerkamp reports research funding in kind from Tricumed. B Groot Koerkamp reports being a speaker for Boston Scientific on HAIP chemotherapy and SIRT in 2026.
